Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technologies are designed to enhance the brain's intrinsic capacity for self-healing and mitigate the effects of neurological diseases or trauma. A prime example of their work is the development of an investigational portable neuromodulation stimulator. This device uniquely delivers neurostimulation through the tongue. Clinical studies have indicated that this approach significantly enhances the efficacy of physical exercises for individuals experiencing neurological symptoms stemming from conditions like disease or trauma, including mild-to-moderate traumatic brain injury. Established on March 13, 2014, Solana Co. maintains its headquarters in Newtown, Pennsylvania.
Solana Company (NASDAQ: HSDT) Announces Pricing of $15 Million Registered Direct Offering with a Global Institutional Investor
Solana Company (HSDT) priced a $15 million registered direct offering of 4,369,356 Class A shares at $3.433 per share with a single institutional investor.
The shares priced at a 5% premium to NAV, with accompanying warrants exercisable at $3.776 (a 10% NAV premium) — an above-NAV raise rather than a dilutive discount.
Proceeds will support growth in SOL per share via opportunistic buybacks and potential Solana treasury purchases; as of September 24, 2026, the company held 2.3 million SOL and total NAV of $278 million.